Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE:300573)
China
· Delayed Price · Currency is CNY 71.23
+0.55 (0.78%)
Apr 29, 2026, 11:55 AM CST
SHE:300573 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 2,600 | 2,453 | 1,924 | 1,440 | 1,227 | 1,024 | Upgrade
|
| Other Revenue | 19.92 | 19.92 | 19.49 | 27.86 | 23.2 | 3.6 | Upgrade
|
| Revenue | 2,620 | 2,473 | 1,943 | 1,468 | 1,250 | 1,028 | Upgrade
|
| Revenue Growth (YoY) | 23.03% | 27.24% | 32.42% | 17.42% | 21.59% | 49.26% | Upgrade
|
| Cost of Revenue | 494.19 | 477.94 | 424.53 | 340.36 | 270.08 | 229.01 | Upgrade
|
| Gross Profit | 2,126 | 1,995 | 1,519 | 1,127 | 979.78 | 798.91 | Upgrade
|
| Selling, General & Admin | 974.5 | 938.52 | 875.78 | 689.8 | 595.39 | 456.54 | Upgrade
|
| Research & Development | 263.31 | 225.91 | 220.66 | 167.3 | 145.61 | 88.45 | Upgrade
|
| Other Operating Expenses | 32.43 | 18.92 | 10.68 | 7.16 | 6.66 | 13.8 | Upgrade
|
| Operating Expenses | 1,271 | 1,184 | 1,110 | 867.29 | 748.58 | 558.6 | Upgrade
|
| Operating Income | 854.39 | 810.48 | 408.42 | 259.93 | 231.2 | 240.31 | Upgrade
|
| Interest Expense | -3.42 | -4.44 | -5.71 | -1.44 | -0.94 | -5.99 | Upgrade
|
| Interest & Investment Income | 1.94 | 2.25 | 5.66 | 7.91 | 9.93 | 3.98 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.67 | -1.67 | -0.11 | 0.2 | -0.09 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.09 | -1.49 | -2.11 | -1.15 | -19.31 | -1.05 | Upgrade
|
| EBT Excluding Unusual Items | 851.34 | 805.14 | 406.15 | 265.45 | 220.79 | 237.12 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.02 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.02 | 0.05 | -0.98 | -0.04 | 0.42 | 5.16 | Upgrade
|
| Asset Writedown | 2.67 | -3.7 | -14.05 | - | -0 | -0 | Upgrade
|
| Other Unusual Items | -1.13 | -1.22 | 3.94 | -0.42 | 12.51 | 1.26 | Upgrade
|
| Pretax Income | 852.86 | 800.28 | 395.03 | 264.99 | 233.72 | 243.54 | Upgrade
|
| Income Tax Expense | 96.49 | 104.42 | 56.97 | 24.96 | 22.03 | 34.43 | Upgrade
|
| Earnings From Continuing Operations | 756.37 | 695.86 | 338.06 | 240.04 | 211.68 | 209.11 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | -14.41 | Upgrade
|
| Net Income | 756.37 | 695.86 | 338.06 | 240.04 | 211.68 | 194.7 | Upgrade
|
| Net Income to Common | 756.37 | 695.86 | 338.06 | 240.04 | 211.68 | 194.7 | Upgrade
|
| Net Income Growth | 68.38% | 105.84% | 40.84% | 13.39% | 8.72% | 121.31% | Upgrade
|
| Shares Outstanding (Basic) | 245 | 246 | 245 | 244 | 241 | 224 | Upgrade
|
| Shares Outstanding (Diluted) | 245 | 246 | 245 | 244 | 241 | 224 | Upgrade
|
| Shares Change (YoY) | -0.20% | 0.37% | 0.60% | 0.96% | 7.45% | -0.30% | Upgrade
|
| EPS (Basic) | 3.08 | 2.83 | 1.38 | 0.99 | 0.88 | 0.87 | Upgrade
|
| EPS (Diluted) | 3.08 | 2.83 | 1.38 | 0.99 | 0.88 | 0.87 | Upgrade
|
| EPS Growth | 68.72% | 105.07% | 40.00% | 12.32% | 1.19% | 120.40% | Upgrade
|
| Free Cash Flow | 507.4 | 482.86 | 218.27 | 55.61 | -12.96 | 211.9 | Upgrade
|
| Free Cash Flow Per Share | 2.07 | 1.96 | 0.89 | 0.23 | -0.05 | 0.94 | Upgrade
|
| Dividend Per Share | 1.700 | 1.700 | 1.071 | 1.888 | 0.547 | 0.237 | Upgrade
|
| Dividend Growth | 58.67% | 58.67% | -43.25% | 245.37% | 130.73% | 160.04% | Upgrade
|
| Gross Margin | 81.14% | 80.67% | 78.16% | 76.81% | 78.39% | 77.72% | Upgrade
|
| Operating Margin | 32.61% | 32.77% | 21.02% | 17.71% | 18.50% | 23.38% | Upgrade
|
| Profit Margin | 28.87% | 28.14% | 17.39% | 16.36% | 16.94% | 18.94% | Upgrade
|
| Free Cash Flow Margin | 19.37% | 19.53% | 11.23% | 3.79% | -1.04% | 20.61% | Upgrade
|
| EBITDA | 957.19 | 911.51 | 502.42 | 340.3 | 297.23 | 297.55 | Upgrade
|
| EBITDA Margin | 36.53% | 36.86% | 25.85% | 23.19% | 23.78% | 28.95% | Upgrade
|
| D&A For EBITDA | 102.8 | 101.04 | 94 | 80.38 | 66.03 | 57.24 | Upgrade
|
| EBIT | 854.39 | 810.48 | 408.42 | 259.93 | 231.2 | 240.31 | Upgrade
|
| EBIT Margin | 32.61% | 32.77% | 21.02% | 17.71% | 18.50% | 23.38% | Upgrade
|
| Effective Tax Rate | 11.31% | 13.05% | 14.42% | 9.42% | 9.43% | 14.14% | Upgrade
|
| Revenue as Reported | 2,620 | 2,473 | 1,943 | 1,468 | 1,250 | 1,028 | Upgrade
|
| Advertising Expenses | - | - | - | 13.81 | 13 | 5.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.